M&A
confidence high
sentiment positive
materiality 0.70
FOXO licenses epigenetics IP to founder's entity; 3% royalty capped at $1.3M, 40% equity option
FOXO TECHNOLOGIES INC.
- Exclusive worldwide license of two U.S. patents, 13,000+ dataset, and ML models to LongevityFP Technologies, controlled by founder Jon R. Sabes.
- Royalty of 3% of net revenues from commercialization, aggregate cap of $1.3 million.
- Ten-year option for LongevityFP to acquire majority (60% or 100%) of FOXO Labs; if exercised, FOXO gets 40% equity interest.
- Agreement includes mutual releases resolving all prior matters between FOXO and founder Jon Sabes.
- FOXO retains ownership of FOXO Labs and all licensed IP throughout the license period.